SEC Comment Letter 0000000000-24-007051 to Aptevo Therapeutics Inc. (APVO)
Aptevo Therapeutics Inc.
Date: June 20, 2024 · CIK: 0001671584 · Accession: 0000000000-24-007051
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-280226
Letter
United States securities and exchange commission logo June 20, 2024 Marvin L. White Chief Executive Officer Aptevo Therapeutics Inc. 2401 4th Avenue, Suite 1050 Seattle, Washington 98121 Re:Aptevo Therapeutics Inc. Registration Statement on Form S-1 Filed June 14, 2024 File No. 333-280226 Dear Marvin L. White: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Sean Donahue
Show Raw Text
United States securities and exchange commission logo
June 20, 2024
Marvin L. White
Chief Executive Officer
Aptevo Therapeutics Inc.
2401 4th Avenue, Suite 1050
Seattle, Washington 98121
Re:Aptevo Therapeutics Inc.
Registration Statement on Form S-1
Filed June 14, 2024
File No. 333-280226
Dear Marvin L. White:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Sean Donahue